This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis (NVS) Plans to Spin Off Generics Business Sandoz
by Zacks Equity Research
Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.
Is Dynavax Technologies (DVAX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold
by Zacks Equity Research
Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.
Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up
by Zacks Equity Research
Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.
Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval
by Zacks Equity Research
Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
by Zacks Equity Research
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.
Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt
by Zacks Equity Research
Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.
Gilead (GILD) Announces Positive Data on Breast Cancer Drug
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.
Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
Roche (RHHBY) Influenza Drug Gets FDA Nod for Children
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.
Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down
by Zacks Equity Research
Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.
Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 92%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 92.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Dynavax Technologies (DVAX) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.
bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 290.91% and 73.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues in the second quarter.
Is Axonics (AXNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped
by Zacks Equity Research
Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.
Wall Street Analysts See an 111% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 111.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Exact Sciences (EXAS) Surges 6.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Myovant Sciences (MYOV) Moves 7.7% Higher: Will This Strength Last?
by Zacks Equity Research
Myovant Sciences (MYOV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA
by Zacks Equity Research
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?